Literature DB >> 30742561

Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.

Mitch Dowsett1,2, Nicholas Turner1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30742561     DOI： 10.1200/JCO.18.01412

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.

Authors:  Joseph A Sparano; Robert Gray
Journal:  J Clin Oncol       Date:  2019-06-07       Impact factor: 44.544

2.  Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Peter M Ravdin; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2019-06-03       Impact factor: 91.245

Review 3.  Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

Authors:  A Matikas; T Foukakis; S Swain; J Bergh
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

Review 4.  Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.

Authors:  Paolo Giorgi Rossi; Annette Lebeau; Carlos Canelo-Aybar; Zuleika Saz-Parkinson; Cecily Quinn; Miranda Langendam; Helen Mcgarrigle; Sue Warman; David Rigau; Pablo Alonso-Coello; Mireille Broeders; Axel Graewingholt; Margarita Posso; Stephen Duffy; Holger J Schünemann
Journal:  Br J Cancer       Date:  2021-02-18       Impact factor: 7.640

5.  Miller-Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy.

Authors:  Liye Wang; Rongzhen Luo; Qianyi Lu; Kuikui Jiang; Ruoxi Hong; Kaping Lee; Ping Zhang; Danyang Zhou; Shusen Wang; Fei Xu
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

6.  Circulating Cell-Free DNA Reflects the Clonal Evolution of Breast Cancer Tumors.

Authors:  Jouni Kujala; Jaana M Hartikainen; Maria Tengström; Reijo Sironen; Päivi Auvinen; Veli-Matti Kosma; Arto Mannermaa
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

7.  Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.

Authors:  Jinani Jayasekera; Joseph A Sparano; Robert Gray; Claudine Isaacs; Allison Kurian; Suzanne O'Neill; Clyde B Schechter; Jeanne Mandelblatt
Journal:  JNCI Cancer Spectr       Date:  2019-08-10

8.  Management of early breast cancer during the COVID-19 pandemic in Brazil.

Authors:  Francisco Pimentel Cavalcante; Guilherme Garcia Novita; Eduardo Camargo Millen; Felipe Pereira Zerwes; Vilmar Marques de Oliveira; Ana Luiza Lima Sousa; Ruffo Freitas Junior
Journal:  Breast Cancer Res Treat       Date:  2020-08-16       Impact factor: 4.872
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.